Compare TCI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | PRTA |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.6M | 538.3M |
| IPO Year | N/A | N/A |
| Metric | TCI | PRTA |
|---|---|---|
| Price | $52.73 | $9.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.86 |
| AVG Volume (30 Days) | 2.2K | ★ 517.2K |
| Earning Date | 11-06-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.87 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $48,675,000.00 | $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,183.79 |
| P/E Ratio | $81.12 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.50 | $4.32 |
| 52 Week High | $59.65 | $16.67 |
| Indicator | TCI | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.59 | 53.04 |
| Support Level | $49.91 | $8.65 |
| Resistance Level | $53.94 | $10.53 |
| Average True Range (ATR) | 1.72 | 0.44 |
| MACD | -0.45 | 0.13 |
| Stochastic Oscillator | 34.95 | 60.64 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.